Thrombosis Research
Volume 122, Issue 3 , Pages 328-335 , 2008

The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients

  • Krystyna Pawlak

      Affiliations

    • Department of Monitored Pharmacotherapy, Medical University of Bialystok, Mickiewicza 2C Street, 15-089 Bialystok, Poland
    • Corresponding Author InformationCorresponding author. Tel./fax: +48 85 7485601.
    • ,
  • Michal Mysliwiec

      Affiliations

    • Department of Nephrology and Clinical Transplantation, Medical University, Bialystok, Poland
    • ,
  • Dariusz Pawlak

      Affiliations

    • Department of Monitored Pharmacotherapy, Medical University of Bialystok, Mickiewicza 2C Street, 15-089 Bialystok, Poland

Received 4 June 2007 ,Revised 14 September 2007 ,Accepted 23 October 2007.

References 

  1. Amann K, Ritz C, Adamczak M, Ritz E. Why is coronary heart disease of uraemic patients so frequent and so devastating?. Nephrol Dial Transplant. 2003;18:631–640
  2. Libby P. Changing concepts of atherogenesis. J Intern Med. 2000;247:349–358
  3. Steins MB, Padro T, Schwaenen C, Ruiz S, Mesters RM, Berdel WE, et al. Overexpression of urokinase receptor and cell surface urokinase-type plasminogen activator in the human vessel wall with different types of atherosclerotic lesions. Blood Coagul Fibrinolysis. 2004;15:383–391
  4. Gyetko MR, Todd RF, Wilkinson CC, Sitrin RG. The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest. 1994;93:1380–1387
  5. Sitrin RG, Togg RF, Albrecht E, Gyetko MR. The urokinase receptor (CD87) facilitates CD11b/CD18-mediated adhesion of human monocytes. J Clin Invest. 1996;97:1942–1951
  6. Yebra M, Parry GCN, Stromblad S, Mackman N, Rosenberg S, Mueller BM, et al. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration. J Biol Chem. 1996;271:29393–29399
  7. Rollins BJ. Chemokines. Blood. 1997;90:909–928
  8. Peters W, Charo IF. Involvement of chemokine receptor 2 and its ligand, monocyte chemoattractant protein-1, in the development of atherosclerosis: lessons from knockout mice. Curr Opin Lipidol. 2001;12:175–180
  9. Wilcox JN, Nelken NA, Coughlin SR, Gordon D, Schall TJ. Local expression of inflammatory cytokines in human atherosclerotic plaques. J Atheroscler Thromb. 1994;1:S3–S10
  10. Pawlak K, Naumnik B, Brzósko S, Pawlak D, Myśliwiec M. Oxidative stress—a link between endothelial injury, coagulation activation and atherosclerosis in haemodialysis patients. Am J Nephrol. 2004;24:154–161
  11. Pawlak K, Pawlak D, Brzosko S, Mysliwiec M. Carotid atherosclerosis is associated with enhanced β-chemokine levels in patients on continuous ambulatory peritoneal dialysis. Atherosclerosis. 2006;186:146–151
  12. Pawlak K, Pawlak D, Mysliwiec M. Oxidative stress effects fibrinolytic system in dialysis uraemic patients. Thromb Res. 2006;117:517–522
  13. Mysliwiec K, Pawlak D, Pawlak M. Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity. Thromb Res. 2007;119:475–480
  14. Nakayama M, Yoshida E, Sugiki M, Anai K, Maruyama M, Maruyama H. Up-regulation of the urokinase-type plasminogen activator receptor by monocyte chemotactic proteins. Blood Coagul Fibrinolysis. 2002;13:383–391
  15. Boyle MDP, Chiodo VA, Lawman MJP, Gee AP, Young M. Urokinase: a chemotactic factor for polymorphonuclear leukocytes in vivo. J Immunol. 1987;139:169–174
  16. Wainberg MA, Israel E, Margolese RG. Further studies on the mitogenic and immune-modulating effects of plasminogen activator. Immunology. 1982;45:715–720
  17. May AE, Schmidt R, Kanse SM, Chavakis T, Chavakis RW, Chavakis A, et al. Urokinase receptor surface expression regulates monocyte adhesion in acute myocardial infarction. Blood. 2002;100:3611–3617
  18. Kirchheimer JC, Remold HG. Endogenous receptor-bound urokinase mediates tissue invasion of human monocytes. J Immunol. 1989;143:2634–2639
  19. Montuori N, Salzano S, Rossi G, Ragno P. Urokinase-type plasminogen activator up-regulates the expression of its cellular receptor. FEBS Lett. 2000;476:166–170
  20. Sitrin RG, Todd RF, Mizukami IF, Gross TJ, Shollenberg SB, Gyetko MR. Cytokine-specific regulation of urokinase receptor (CD87) expression by U937 mononuclear phagocytes. Blood. 1994;84:1268–1275
  21. Chavakis T, Kanse SM, Yutzy B, Lijnen HR, Preissner KT. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complex. Blood. 1998;91:2305–2312
  22. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, et al. Regulation of integrin function by urokinase receptor. Science. 1996;273:1551–1555
  23. Fazioli F, Resnati M, Sidenius N, Higashimoto Y, Appella E, Blasi F. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J. 1997;16:7279–7286

PII: S0049-3848(07)00404-5

doi: 10.1016/j.thromres.2007.10.017

Thrombosis Research
Volume 122, Issue 3 , Pages 328-335 , 2008

Article Tools

* Image Usage & Resolution